The Phase I clinical trial is a randomized, single-blind, placebo-controlled, single-ascending dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of orally administered ARRY-300 in healthy volunteers.
Kevin Koch, president and chief scientific officer of Array BioPharma, said: “We believe ARRY-300 is a best-in-class MEK inhibitor with superior pharmacologic properties compared to other MEK inhibitors currently in clinical development. Initially, we plan to test ARRY-300 in healthy volunteers to evaluate its safety, pharmacokinetics and pharmacodynamics.”